欧洲多发性硬化治疗和研究委员会（European Committee of Treatment and Research in Multiple Sclerosis，ECTRIMS）和欧洲神经病学学会（European Academy of Neurology，EAN）共同发布了最新的、基于证据的多发性硬化（multiple sclerosis, MS）药物治疗指南，以指导MS 患者药物治疗和医疗专业人员治疗决策。指南对成人MS和临床孤立综合征（clinically isolated syndrome，CIS）患者的药物修饰治疗（diseasemodifying treatment，DMT）提出20 条建议，内容涵盖了治疗有效性、治疗反应监测、治疗反应不充分的治疗策略、停止和更换治疗策略以及特殊情况下（如妊娠患者）的药物治疗。本文对该指南要点进行介绍，并予以解读。

The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have joined to develop an up-to-date and evidence-based clinical practice guideline for the pharmacological treatment of people with multiple sclerosis (MS) to guide healthcare professionals in the decision-making process. This guideline focuses on disease-modifying treatment (DMT) for the adult patients with confirmed MS and clinically isolated syndrome (CIS) and a total of 20 recommendations have been agreed, encompassing treatment efficacy, monitoring of treatment response, strategies for inadequate treatment response, treatment discontinuation and/or switch, as well as treatment in special situations (such as pregnancy). This paper presents the highlights of the guideline and gives some comments.